Society guideline links: Rheumatoid arthritis

Introduction — 

This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately:

●(See "Society guideline links: NSAID-related ulcer complications".)

●(See "Society guideline links: Sjögren's disease".)

●(See "Society guideline links: Undifferentiated early inflammatory arthritis".)

●(See "Society guideline links: Juvenile idiopathic arthritis".)

International

●International Task Force: Recommendations for treating rheumatoid arthritis to target, 2014 update (published 2016)

Canada

●Canadian Rheumatology Association (CRA): Living guidelines for rheumatoid arthritis, update #2 (2024)

●Choosing Wisely Canada: Don't order rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) unless patients have clinically suspicious arthralgia (CSA) or arthritis on exam (2024)

●CRA: Position statement on the safety of hydroxychloroquine in the treatment of rheumatic diseases (2021)

United States

●American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST): Guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases, 2023 (published 2024)

●ACR/CHEST: Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases, 2023 (published 2024)

●ACR: Guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis (2022)

●ACR: Guideline for the treatment of rheumatoid arthritis (2021)

●ACR: Recommended patient-reported functional status assessment measures in rheumatoid arthritis (2019)

●ACR: Recommended rheumatoid arthritis disease activity measures, update (2019)

●American College of Radiology (ACR): ACR Appropriateness Criteria on chronic extremity joint pain-suspected inflammatory arthritis (2016)

Europe

●European League Against Rheumatism (EULAR): Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, 2022 (published 2023)

●EULAR: Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis (2018)

●EULAR: Recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders, 2015/2016 update (published 2017)

●EULAR: Recommendations for the management of early arthritis, 2016 update (published 2017)

●EULAR: Recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis (2013)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Guideline on rheumatoid arthritis in adults – Management (2018, updated 2020)

●NICE: Quality standard on rheumatoid arthritis in over 16s (2013, updated 2020)

●NICE: Diagnostics guidance on the therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (2019)

India

●Asia Pacific League of Associations for Rheumatology (APLAR): Recommendations for treatment of rheumatoid arthritis, 2018 update (published 2019)

Australia–New Zealand

●Asia Pacific League of Associations for Rheumatology (APLAR): Recommendations for treatment of rheumatoid arthritis, 2018 update (published 2019)

Japan

●[In Japanese] Japanese College of Rheumatology (JCR): Guidance for abatacept use in rheumatoid arthritis (RA) (2024)

●[In Japanese] JCR: Guidance for the use of IL-6 inhibitors for rheumatoid arthritis (RA) (2024)

●[In Japanese] JCR: Guidance for the use of TNF inhibitors in rheumatoid arthritis (RA) (2024)

●[In Japanese] JCR: Guidance for the use of tofacitinib in rheumatoid arthritis (RA) (2023)

●[In English] JCR: Drug treatment algorithm and recommendations from the 2020 update of the clinical practice guidelines for the management of rheumatoid arthritis – Secondary publication (published 2022)

●[In Japanese] JCR: Guide to using denosumab for rheumatoid arthritis (2020)

●[In English] Asia Pacific League of Associations for Rheumatology (APLAR): Recommendations for treatment of rheumatoid arthritis, 2018 update (published 2019)

●[In English] JCR: Guideline for the use of methotrexate in patients with rheumatoid arthritis (2019)

●[In Japanese] Choosing Wisely Japan: Rheumatoid arthritis treatment – Nonbiological agents preferred as first choice (2016)

●[In Japanese] JCR: Methotrexate (MTX) practice guideline for the treatment of rheumatoid arthritis, revised edition (2016)

●[In Japanese] JCR: Rheumatoid arthritis practice guidelines (2014)